Accurate preoperative prediction of major pathological response or pathological complete response after neoadjuvant chemo-immunotherapy remains a critical unmet need in resectable non-small-cell lung cancer (NSCLC).
Conventional size-based imaging criteria offer limited reliability, while biopsy confirmation is available only post-surgery.
